BIOCRYST PHARMACEUTICALS INC (BCRX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US09058V1035
BIOCRYST PHARMACEUTICALS INC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 874.84 m USD |
| Gross profit | 855.76 m USD |
| Operating income | 340.99 m USD |
| EBIT | 346.26 m USD |
| Net income | 263.86 m USD |
| Diluted EPS – continuing operations | 1.21 USD |
Full history since 1994, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About BIOCRYST PHARMACEUTICALS INC
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
More stocks
- KCC Corporation (002380.KS)
- Tibet GaoZheng Explosive Co Ltd (002827.SZ)
- Dongyue Group Ltd (189.HK)
- CNNC Hua Yuan Titanium Dioxide Co Ltd (002145.SZ)
- Zhejiang Yonghe Refrigerant Co Ltd (605020.SS)
- 1ST SOURCE CORP (SRCE)
- Progyny, Inc. (PGNY)
- Beijing Jetsen Tech Co (300182.SZ)
- Triputra Agro Persada Tbk PT (TAPG.JK)
- ManpowerGroup Inc. (MAN)
- Pony AI Inc. American Depositary Shares (PONY)
- Immunome Inc. (IMNM)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.